HUP0102444A2 - Protein-C származékok - Google Patents

Protein-C származékok

Info

Publication number
HUP0102444A2
HUP0102444A2 HU0102444A HUP0102444A HUP0102444A2 HU P0102444 A2 HUP0102444 A2 HU P0102444A2 HU 0102444 A HU0102444 A HU 0102444A HU P0102444 A HUP0102444 A HU P0102444A HU P0102444 A2 HUP0102444 A2 HU P0102444A2
Authority
HU
Hungary
Prior art keywords
protein
diseases
derivatives
wild
type human
Prior art date
Application number
HU0102444A
Other languages
English (en)
Inventor
Bruce Edward Gerlitz
Bryan Edward Jones
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0102444A2 publication Critical patent/HUP0102444A2/hu
Publication of HUP0102444A3 publication Critical patent/HUP0102444A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)

Abstract

A találmányban új protein-C származékokat írtak le. Ezek apolipeptidek a vadtípusú humán protein-C biológiai aktivitásátmegtartják, de a vérplazmában lényegesen hosszabb féléletidővelrendelkeznek. Ezek a következő betegségek kezelésekor a polipeptidekvagy kisebb gyakoriságú beadását és/vagy kisebb dózisok beadásátigénylik, mint a vadtípusú humán protein-C: vaszkuláris elzáródásibetegségek, hiperkoagulábilis állapotok, trombotikus betegségek éstrombózisra hajlamosító kórállapotok. Ó
HU0102444A 1999-04-30 2000-04-13 Protein c derivatives HUP0102444A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13180199P 1999-04-30 1999-04-30
PCT/US2000/008722 WO2000066754A1 (en) 1999-04-30 2000-04-13 Protein c derivatives

Publications (2)

Publication Number Publication Date
HUP0102444A2 true HUP0102444A2 (hu) 2001-10-28
HUP0102444A3 HUP0102444A3 (en) 2003-09-29

Family

ID=22451086

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102444A HUP0102444A3 (en) 1999-04-30 2000-04-13 Protein c derivatives

Country Status (11)

Country Link
EP (1) EP1090130A1 (hu)
JP (1) JP2002542832A (hu)
KR (1) KR20010053345A (hu)
AR (1) AR029627A1 (hu)
AU (1) AU4188500A (hu)
BR (1) BR0006088A (hu)
CA (1) CA2338799A1 (hu)
HU (1) HUP0102444A3 (hu)
IL (1) IL140326A0 (hu)
PE (1) PE20010066A1 (hu)
WO (1) WO2000066754A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326356A (zh) * 1998-11-20 2001-12-12 伊莱利利公司 治疗病毒性出血热的方法
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
DE60108076T2 (de) * 2000-02-02 2006-03-16 Eli Lilly And Co., Indianapolis Protein c derivate
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
AU2001292308A1 (en) * 2000-09-30 2002-04-15 Mochida Pharmaceutical Co., Ltd. Preventives/remedies for hemolytic anemia
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2002032461A2 (en) * 2000-10-18 2002-04-25 Maxygen Aps Protein c or activated protein c-like molecules
WO2006044294A2 (en) * 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
WO2023171719A1 (ja) * 2022-03-08 2023-09-14 学校法人自治医科大学 活性化プロテインｃ配列

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7168591A (en) * 1989-12-29 1991-07-24 Zymogenetics Inc. Hybrid protein c
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
ATE321846T1 (de) * 1996-11-08 2006-04-15 Oklahoma Med Res Found Verwendung eines modifizierten protein-c

Also Published As

Publication number Publication date
PE20010066A1 (es) 2001-02-02
EP1090130A1 (en) 2001-04-11
AR029627A1 (es) 2003-07-10
KR20010053345A (ko) 2001-06-25
IL140326A0 (en) 2002-02-10
AU4188500A (en) 2000-11-17
HUP0102444A3 (en) 2003-09-29
CA2338799A1 (en) 2000-11-09
WO2000066754A1 (en) 2000-11-09
BR0006088A (pt) 2001-03-20
JP2002542832A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
TW200711657A (en) Pharmaceutical composition comprising botulinum toxin and recombinant human serum albumin
DK0910647T3 (da) Human DNase i hyperaktive varianter
HUP0301246A2 (hu) Humán véralvadási faktor VII változatai
HK1069316A1 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
HUP0400882A2 (hu) Onkolitikus vírusterápia
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
HUP0103889A2 (hu) Kopolimer-1-rokon polipeptidek alkalmazása molekulatömeg kalibráló standardként és gyógyászati anyagként
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE69331739T2 (de) Neuartige pharmazeutische verwendungen von krill-enzymen
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
SE8902532D0 (sv) Bestaemning av plasmaproteiner
PT1126870E (pt) Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose
HK1068606A1 (en) Novel aminobenzoephenones
HUP0102444A2 (hu) Protein-C származékok
AU2001232736A1 (en) Protein c derivatives
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
WO2001036462A3 (en) Protein c derivatives
ATE254595T1 (de) 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten
ATE265225T1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
IT1283899B1 (it) Peptidi e loro usi nella terapia della malattia celiaca
DE69836278D1 (de) Allele formen von menschlichem stat3